<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590562</url>
  </required_header>
  <id_info>
    <org_study_id>ML28487</org_study_id>
    <nct_id>NCT02590562</nct_id>
  </id_info>
  <brief_title>An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.</brief_title>
  <official_title>A Multi-center Cross-sectional Study on Treatment Patterns and Patient Characteristics in Rheumatoid Arthritis (RA) Patients Treated by Biological DMARDs in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This observational study will describe the treatment patterns of usage of biological DMARDs
      in routine clinical practice and the demographics and RA disease characteristics in patients
      suffering from rheumatoid arthritis. Patients will be recruited and examined the same day
      when recruited. There will be no follow up visit or treatment period only one visit in this
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 31, 2013</start_date>
  <completion_date type="Actual">August 31, 2014</completion_date>
  <primary_completion_date type="Actual">August 31, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Receiving Biological Agent as Monotherapy or in Combination With Conventional Synthesis Disease-modifying Anti-rheumatic Drugs (csDMARDs) Therapy</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Biological agent monotherapy meant participants using a biological agent without concomitant csDMARDs. Biological agent monotherapy included biological agent only, biological agent + glucocorticoid, biological agent + non-steroidal anti-inflammatory drugs [NSAIDs], and biological agent + glucocorticoid + NSAIDs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Receiving a Biological Agent Concomitant With Other Drugs</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Number of participants receiving treatment of a biological agent concomitant with the following drugs: glucocorticoid, NSAIDs, other external medicine, or concomitant glucocorticoid and concomitant NSAIDs. The same participant could use 2 or 3 of concomitant glucocorticoid, NSAIDs and other external medicine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Receiving a Biological Agent as Monotherapy by Types of Biological Agents</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Number of participants who received a biological agent as monotherapy is presented by biological agent (adalimumab, tocilizumab, etanercept, and infliximab).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Weekly Dose of Treatment for Each Biological Agent</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Average weekly dose of treatment of each biological agent (adalimumab, tocilizumab, etanercept, or infliximab) is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Duration of Treatment for Each Biological Agent</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Average duration of treatment of each biological agent (adalimumab, tocilizumab, etanercept, or infliximab) is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Previous Use of the Same Biological Agent</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Participants who used the same biological agent in the past and were using that same biological agent at the time of study enrollment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reasons for Switching Types of Biological Agent Who Used a Different Biological Agent in the Past</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Participants who used a different biological agent in the past and switched are shown by reason for switching. One participant could have switched types of biological agent due to multiple reasons.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Weekly Dose of Each Concomitant Glucocorticoid</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Average weekly dose of each concomitant glucocorticoid (prednisone acetate, oral; betamethasone [BMZ] dipropionate and betamethasone sodium phosphate, intra-articular (IA) injection; and methylprednisolone, intravenous drip infusion, oral) is presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Duration of Treatment With Each Concomitant External Medicine</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Using One, Two, or Three (or More) Concomitant csDMARDs</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Number of participants using one concomitant csDMARD, two concomitant csDMARDs (methotrexate + hydroxychloroquine [HCQ], methotrexate + salazosulfapyridine [SASP], methotrexate+ leflunomide, SASP + HCQ, and other combinations), or three (or more) concomitant csDMARDs (methotrexate + SASP + HCQ, and other combinations) are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Weekly Dose of Each Concomitant csDMARD</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>One participant could have received multiple concomitant csDMARDs treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Duration of Treatment With Each Concomitant csDMARD</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>One participant could have received multiple concomitant csDMARDs treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Daily Dose of Each Currently Concomitant NSAIDs</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>One participant could have received multiple concomitant NSAIDs treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average Daily Dose of Each Previously Concomitant NSAIDs</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>One participant could have received multiple concomitant NSAIDs treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Participants With Past Medical History of Concurrent Chronic Disease, Tuberculosis, Hepatitis, and Imaging Manifestations of Joint Damage</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of RA Related Operations</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>RA related operations also included prosthesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA Duration Since Diagnosis</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>RA duration = (the date of participants signing the informed consent form - date of RA diagnosis + 1) /365.25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With RA Duration</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Number of participants with RA duration of &lt;= 6 months, &gt;6 months and &lt;= 3 years, &gt;3 years and &lt;= 10 years, and 10 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Concurrent RA Extra-articular Symptoms</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Number of participants with concurrent RA extra-articular symptoms including RA subcutaneous nodule, RA vasculitis, interstitial pneumonia, Felty's syndrome, and other symptoms were presented. One participant could have more than one concurrent RA extra-articular symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Concurrent Interstitial Lung Disease Using Methotrexate</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP) Values</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal CRP Values</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Central lab was not used in this study; the definitions of abnormal CRP followed participating hospitals' standardized criteria. Case report form (CRF) collected data as directly &quot;normal&quot; or &quot;abnormal&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate (ESR) Values</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. A higher rate is consistent with inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal ESR Values</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. A higher rate is consistent with inflammation. Central lab was not used in this study; the definitions of abnormal ESR followed participating hospitals' standardized criteria. CRF collected data as directly &quot;normal&quot; or &quot;abnormal&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Values</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Hemoglobin levels were measured in gram per liter (g/L). Anemia was defined as an adult male with hemoglobin value &lt;120 g/L or an adult female with hemoglobin value &lt;110 g/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anemia</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Anemia was defined as an adult male with hemoglobin value &lt;120 g/L or an adult female with hemoglobin value &lt;110 g/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Anti-cyclic Citrullinated Peptide (ACCP) Antibody</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>ACCP antibodies are important markers of bone erosion in RA. Central lab was not used in this study; the definitions of positive ACCP followed participating hospitals' standardized criteria. CRF collected data as &quot;positive&quot; or &quot;negative&quot; directly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Positive Rheumatoid Factor (RF)</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. Central lab was not used in this study; the definitions of positive RF followed participating hospitals' standardized criteria. CRF collected data as &quot;positive&quot; or &quot;negative&quot; directly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglyceride Values</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Normal range for triglyceride is &lt;1.7 millimoles per liter (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Triglyceride Values</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Normal range for triglyceride is &lt;1.7 mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol Values</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Normal range for total cholesterol is &lt;5.2 mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Total Cholesterol Values</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Normal range for total cholesterol is &lt;5.2 mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joint Count (SJC)</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender Joint Count (TJC)</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Based on 28-Joint Count (DAS28)</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and Patient's Global Assessment (PtGA) of disease activity (measured on a 0 to 100 mm Visual Analogue Scale [VAS] where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*square root (sqrt) (TJC28) + 0.28*sqrt(SJC28) + 0.70*natural logarithm (ln) (ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA of disease activity. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing High Disease Activity to Clinical Remission Using the DAS28</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and PtGA of disease activity (measured on a 0 to 100 mm VAS where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA of disease activity. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index (CDAI) Scores</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and Physician's Global Assessment (PGA) assessed on 0-10 centimeter (cm) VAS; 0 = no disease activity and 10 = worst disease activity. CDAI total score = 0-76. CDAI &lt;= 2.8 indicates clinical remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high (or severe) disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing High Disease Activity to Clinical Remission Using the CDAI</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity. CDAI total score = 0-76. CDAI &lt;= 2.8 indicates clinical remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high (or severe) disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity, and CRP (mg/dL). SDAI total score = 0-86. SDAI &lt;=3.3 indicates clinical remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high (or severe) disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing High Disease Activity to Clinical Remission Using the SDAI</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity, and CRP (mg/dL). SDAI total score = 0-86. SDAI &lt;=3.3 indicates clinical remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high (or severe) disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Duration of Treatment of Biological Agent</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Number of participants with duration of treatment of biological agent &lt;3 months, &gt;= 3 to &lt;6 months, &gt;= 6 to &lt;12 months, and &gt;= 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 by Duration of Treatment of Biological Agent</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and PtGA of disease activity (measured on a 0 to 100 mm VAS where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA of disease activity. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28 by Biological Agent as Monotherapy or Combination With csDMARDs</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Biological agent monotherapy meant participants using a biological agent without concomitant csDMARDs. DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and PtGA of disease activity (measured on a 0 to 100 mm VAS where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment (PGA) of Disease Activity</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>PGA of disease activity was measured on a 0 to 10 centimeter (cm) VAS, with 0 cm = no disease activity and 10 cm = extreme disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Assessment (PtGA) of Disease Activity</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>PtGA of disease activity was measured on a 0 to 10 cm VAS, with 0 cm = very well controlled and 10 cm = very poorly controlled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>The HAQ consists of 20 questions in 8 categories (dressing and grooming, rising, eating, walking, reach, grip, hygiene, and carrying out daily activities). Each question has 4 response options, ranging from &quot;no difficulty&quot; to &quot;unable to do&quot;, corresponding to scores from 0 to 3. HAQ total score = sum of each of the 20 items' scores, with a summary score ranging from 0 to 60, where higher score indicates greater disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Fatigue Assessment</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Participants scored the fatigue on 10 cm VAS from 0 = no fatigue to 10 = very fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Pain Assessment</measure>
    <time_frame>Day 1 (enrollment visit)</time_frame>
    <description>Participants scored the intensity of pain produced by RA on 10 cm VAS from 0 = no pain to 10 = extreme pain.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">808</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>RA patients treated with routine clinical practice</arm_group_label>
    <description>Describe in routine clinical practice the treatment patterns of usage of biological DMARDs in patients suffering from RA including frequency of monotherapy, biological DMARDs usage status (types, dosage), concomitant DMARDs usage information (type and dosage)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine clinical practice</intervention_name>
    <arm_group_label>RA patients treated with routine clinical practice</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include RA patients (according to ACR criteria) who are
        experiencing biologic treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients at least 18 years of age.

          -  Patients with a diagnosis of RA according to the revised ACR criteria.

          -  Patients receiving treatment of launched biological DMARDs.

        Exclusion Criteria:

          -  Patients who received biological DMARDs due to clinical trials or biologics not
             launched.

          -  Patients who are considered not appropriate for study due to other reasons at
             physicians' discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Jishutan Hospital; Rheumatology &amp; Immunology</name>
      <address>
        <city>Beijing</city>
        <zip>100035</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100083</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China-Janpan Friendship Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou University of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <zip>510405</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guanghua Hospital of Integrated Traditional Chinese and Western Medicine ( Guanghua Hospital)</name>
      <address>
        <city>Shanghai</city>
        <zip>200052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin (天津)</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Medical College of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xinjiang Uygur Autonomous Region People Hospital</name>
      <address>
        <city>Ürümqi</city>
        <zip>830001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <results_first_submitted>December 3, 2015</results_first_submitted>
  <results_first_submitted_qc>January 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2016</results_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall Population</title>
          <description>Participants diagnosed with rheumatoid arthritis (RA) according to American College of Rheumatology (ACR) 1987 criteria who were using biological disease-modifying anti-rheumatic drugs (DMARDs) approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="808"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="802"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did Not Meet the Inclusion Criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall Population: Participants who met all inclusion criteria, diagnosed with RA according to ACR 1987 criteria and were using biological DMARDs approved in China for RA treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Population</title>
          <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="802"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age was available for 800 participants only; age was missing for 2 participants who were thus not included in the age results.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="13.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Age was available for 800 participants only; age was missing for 2 participants who were thus not included in the age results.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>less than or equal to (&lt;=) 20 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>greater than (&gt;) 20 to &lt;=40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;40 to &lt;=60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="652"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Receiving Biological Agent as Monotherapy or in Combination With Conventional Synthesis Disease-modifying Anti-rheumatic Drugs (csDMARDs) Therapy</title>
        <description>Biological agent monotherapy meant participants using a biological agent without concomitant csDMARDs. Biological agent monotherapy included biological agent only, biological agent + glucocorticoid, biological agent + non-steroidal anti-inflammatory drugs [NSAIDs], and biological agent + glucocorticoid + NSAIDs.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving Biological Agent as Monotherapy or in Combination With Conventional Synthesis Disease-modifying Anti-rheumatic Drugs (csDMARDs) Therapy</title>
          <description>Biological agent monotherapy meant participants using a biological agent without concomitant csDMARDs. Biological agent monotherapy included biological agent only, biological agent + glucocorticoid, biological agent + non-steroidal anti-inflammatory drugs [NSAIDs], and biological agent + glucocorticoid + NSAIDs.</description>
          <population>Overall Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Biological agent only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biological agent+ glucocorticoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biological agent + NSAIDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biological agent + glucocorticoid + NSAIDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biological agent concomitant with csDMARDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Receiving a Biological Agent Concomitant With Other Drugs</title>
        <description>Number of participants receiving treatment of a biological agent concomitant with the following drugs: glucocorticoid, NSAIDs, other external medicine, or concomitant glucocorticoid and concomitant NSAIDs. The same participant could use 2 or 3 of concomitant glucocorticoid, NSAIDs and other external medicine.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving a Biological Agent Concomitant With Other Drugs</title>
          <description>Number of participants receiving treatment of a biological agent concomitant with the following drugs: glucocorticoid, NSAIDs, other external medicine, or concomitant glucocorticoid and concomitant NSAIDs. The same participant could use 2 or 3 of concomitant glucocorticoid, NSAIDs and other external medicine.</description>
          <population>Overall Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Concomitant with glucocorticoid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant with NSAIDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant with glucocorticoid and NSAIDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concomitant other external medicine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Receiving a Biological Agent as Monotherapy by Types of Biological Agents</title>
        <description>Number of participants who received a biological agent as monotherapy is presented by biological agent (adalimumab, tocilizumab, etanercept, and infliximab).</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Receiving a Biological Agent as Monotherapy by Types of Biological Agents</title>
          <description>Number of participants who received a biological agent as monotherapy is presented by biological agent (adalimumab, tocilizumab, etanercept, and infliximab).</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adalimumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tocilizumab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etanercept</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infliximab</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Weekly Dose of Treatment for Each Biological Agent</title>
        <description>Average weekly dose of treatment of each biological agent (adalimumab, tocilizumab, etanercept, or infliximab) is presented.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with specified treatment of biological agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Weekly Dose of Treatment for Each Biological Agent</title>
          <description>Average weekly dose of treatment of each biological agent (adalimumab, tocilizumab, etanercept, or infliximab) is presented.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with specified treatment of biological agent.</population>
          <units>milligrams (mg) per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="783"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adalimumab (n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tocilizumab (n=136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" spread="21.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etanercept (n=534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2" spread="15.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infliximab (n=53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.1" spread="23.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Duration of Treatment for Each Biological Agent</title>
        <description>Average duration of treatment of each biological agent (adalimumab, tocilizumab, etanercept, or infliximab) is presented.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. n = participants with specified treatment of biological agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Duration of Treatment for Each Biological Agent</title>
          <description>Average duration of treatment of each biological agent (adalimumab, tocilizumab, etanercept, or infliximab) is presented.</description>
          <population>Overall Population. n = participants with specified treatment of biological agent.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adalimumab (n=60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="19.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tocilizumab (n=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" spread="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etanercept (n=535)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="47.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infliximab (n=69)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" spread="39.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Previous Use of the Same Biological Agent</title>
        <description>Participants who used the same biological agent in the past and were using that same biological agent at the time of study enrollment.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Previous Use of the Same Biological Agent</title>
          <description>Participants who used the same biological agent in the past and were using that same biological agent at the time of study enrollment.</description>
          <population>Overall Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reasons for Switching Types of Biological Agent Who Used a Different Biological Agent in the Past</title>
        <description>Participants who used a different biological agent in the past and switched are shown by reason for switching. One participant could have switched types of biological agent due to multiple reasons.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reasons for Switching Types of Biological Agent Who Used a Different Biological Agent in the Past</title>
          <description>Participants who used a different biological agent in the past and switched are shown by reason for switching. One participant could have switched types of biological agent due to multiple reasons.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Economic reasons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsatisfactory efficacy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improvement of the disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inconvenient administration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Voluntarily discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other reasons</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Weekly Dose of Each Concomitant Glucocorticoid</title>
        <description>Average weekly dose of each concomitant glucocorticoid (prednisone acetate, oral; betamethasone [BMZ] dipropionate and betamethasone sodium phosphate, intra-articular (IA) injection; and methylprednisolone, intravenous drip infusion, oral) is presented.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with specified concomitant glucocorticoid treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Weekly Dose of Each Concomitant Glucocorticoid</title>
          <description>Average weekly dose of each concomitant glucocorticoid (prednisone acetate, oral; betamethasone [BMZ] dipropionate and betamethasone sodium phosphate, intra-articular (IA) injection; and methylprednisolone, intravenous drip infusion, oral) is presented.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with specified concomitant glucocorticoid treatment.</population>
          <units>mg/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="235"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Prednisone acetate, oral (n=174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.8" spread="31.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BMZ dipropionate and BMZ sodium phosphate, IA(n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methylprednisolone, intravenous drip infusion(n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="638.8" spread="368.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methylprednisolone, oral (n=55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7" spread="151.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Duration of Treatment With Each Concomitant External Medicine</title>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Duration of Treatment With Each Concomitant External Medicine</title>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baiyi anti-inflammatory analgesic plaster (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tibetan medicine (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flurbiprofen (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Compound Nanxing analgesic plaster (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect moxibustion (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dogskin paste (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="4.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dogskin plaster (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic plaster for arthritis (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" spread="83.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hantongle plaster (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Safflower oil (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wong To Yick Winter Green Oil (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Activating collaterals Liniment (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Flavored Shuangbai Powder (n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" spread="27.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Capsaicin (n=13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Kilo-Mile Medicine Oil (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Qingpeng ointment (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" spread="39.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shuangbai powder (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="4.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diclofenac (n=32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="26.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tianhe ostealgia plaster (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketoprofen (n=46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Xiaotong plaster (n=5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.2" spread="45.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-inflammatory analgesic ointment (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antiphlogistic analgesic ointment (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yunnan Baiyao plaster (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0" spread="84.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chinese patent medicine (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indometacin (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musk tiger bone plaster (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musk analgesic spray (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shexiang Zhuanggu plaster (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Using One, Two, or Three (or More) Concomitant csDMARDs</title>
        <description>Number of participants using one concomitant csDMARD, two concomitant csDMARDs (methotrexate + hydroxychloroquine [HCQ], methotrexate + salazosulfapyridine [SASP], methotrexate+ leflunomide, SASP + HCQ, and other combinations), or three (or more) concomitant csDMARDs (methotrexate + SASP + HCQ, and other combinations) are presented.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Using One, Two, or Three (or More) Concomitant csDMARDs</title>
          <description>Number of participants using one concomitant csDMARD, two concomitant csDMARDs (methotrexate + hydroxychloroquine [HCQ], methotrexate + salazosulfapyridine [SASP], methotrexate+ leflunomide, SASP + HCQ, and other combinations), or three (or more) concomitant csDMARDs (methotrexate + SASP + HCQ, and other combinations) are presented.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="718"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>One csDMARDs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two csDMARDs: Methotrexate + HCQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two csDMARDs: Methotrexate + SASP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two csDMARDs: Methotrexate+ leflunomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two csDMARDs: SASP + HCQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Two csDMARDs: Other combinations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three(or more) csDMARDs: Methotrexate + SASP + HCQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Three (or more) csDMARDs: Other combinations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Weekly Dose of Each Concomitant csDMARD</title>
        <description>One participant could have received multiple concomitant csDMARDs treatment.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Weekly Dose of Each Concomitant csDMARD</title>
          <description>One participant could have received multiple concomitant csDMARDs treatment.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
          <units>mg/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="718"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Iguratimod (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cyclophosphamide (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" spread="18.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ciclosporin (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="35.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methotrexate (n=473)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leflunomide (n=298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4" spread="5.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloroquine phosphate (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Azathioprine (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfasalazine (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1753.3" spread="693.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycophenolate mofetil (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="625.0" spread="530.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minocycline (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Penicillamine (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="343.8" spread="57.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thalidomide (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" spread="28.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydroxychloroquine (n=300)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340.3" spread="96.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Duration of Treatment With Each Concomitant csDMARD</title>
        <description>One participant could have received multiple concomitant csDMARDs treatment.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Duration of Treatment With Each Concomitant csDMARD</title>
          <description>One participant could have received multiple concomitant csDMARDs treatment.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="718"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Iguratimod (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.8" spread="121.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cyclophosphamide (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.1" spread="230.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ciclosporin (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="448.0" spread="554.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Methotrexate (n=468)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="443.7" spread="845.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leflunomide (n=296)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="413.4" spread="578.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloroquine phosphate (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.2">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Azathioprine (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfasalazine (n=45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429.1" spread="1039.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycophenolate mofetil (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minocycline (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Penicillamine (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="768.8" spread="1012.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thalidomide (n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.5" spread="208.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydroxychloroquine (n=298)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.3" spread="409.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Daily Dose of Each Currently Concomitant NSAIDs</title>
        <description>One participant could have received multiple concomitant NSAIDs treatment.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Dose of Each Currently Concomitant NSAIDs</title>
          <description>One participant could have received multiple concomitant NSAIDs treatment.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="450"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Imrecoxib (n=20)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ibuprofen (n=12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550.0" spread="173.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aceclofenac (n=7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157.1" spread="53.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lornoxicam (n=6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loxoprofen sodium (n=54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143.9" spread="45.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meloxicam (n=91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nimesulide (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186.1" spread="41.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Celecoxib (n=194)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.2" spread="100.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diclofenac (n=31)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.6" spread="166.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etoricoxib (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" spread="32.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indometacin (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Average Daily Dose of Each Previously Concomitant NSAIDs</title>
        <description>One participant could have received multiple concomitant NSAIDs treatment.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Average Daily Dose of Each Previously Concomitant NSAIDs</title>
          <description>One participant could have received multiple concomitant NSAIDs treatment.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure. n = participants with available data for specified category.</population>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ibuprofen (n=8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525.0" spread="148.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aceclofenac (n=2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150.0" spread="70.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loxoprofen sodium (n=16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135.0" spread="46.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meloxicam (n=18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nimesulide (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Celecoxib (n=39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.7" spread="95.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diclofenac (n=12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3" spread="40.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Etoricoxib (n=3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indometacin (n=1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0">Standard deviation was not available as there was only 1 participant analyzed for this category.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number Participants With Past Medical History of Concurrent Chronic Disease, Tuberculosis, Hepatitis, and Imaging Manifestations of Joint Damage</title>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number Participants With Past Medical History of Concurrent Chronic Disease, Tuberculosis, Hepatitis, and Imaging Manifestations of Joint Damage</title>
          <population>Overall Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Concurrent chronic disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tuberculosis history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis history</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imaging of joint damage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="799"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="10.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Height</title>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Height</title>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="797"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.6" spread="6.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of RA Related Operations</title>
        <description>RA related operations also included prosthesis.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of RA Related Operations</title>
          <description>RA related operations also included prosthesis.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>RA related operations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="801"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RA Duration Since Diagnosis</title>
        <description>RA duration = (the date of participants signing the informed consent form - date of RA diagnosis + 1) /365.25</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>RA Duration Since Diagnosis</title>
          <description>RA duration = (the date of participants signing the informed consent form - date of RA diagnosis + 1) /365.25</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="5.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With RA Duration</title>
        <description>Number of participants with RA duration of &lt;= 6 months, &gt;6 months and &lt;= 3 years, &gt;3 years and &lt;= 10 years, and 10 years.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With RA Duration</title>
          <description>Number of participants with RA duration of &lt;= 6 months, &gt;6 months and &lt;= 3 years, &gt;3 years and &lt;= 10 years, and 10 years.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;6 months and &lt;=3 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;3 years and &lt;=10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Concurrent RA Extra-articular Symptoms</title>
        <description>Number of participants with concurrent RA extra-articular symptoms including RA subcutaneous nodule, RA vasculitis, interstitial pneumonia, Felty’s syndrome, and other symptoms were presented. One participant could have more than one concurrent RA extra-articular symptoms.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Concurrent RA Extra-articular Symptoms</title>
          <description>Number of participants with concurrent RA extra-articular symptoms including RA subcutaneous nodule, RA vasculitis, interstitial pneumonia, Felty’s syndrome, and other symptoms were presented. One participant could have more than one concurrent RA extra-articular symptoms.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RA nodule</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vasculitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interstitial pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Felty's syndrome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Concurrent Interstitial Lung Disease Using Methotrexate</title>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Concurrent Interstitial Lung Disease Using Methotrexate</title>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-Reactive Protein (CRP) Values</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>C-Reactive Protein (CRP) Values</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="33.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal CRP Values</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Central lab was not used in this study; the definitions of abnormal CRP followed participating hospitals’ standardized criteria. Case report form (CRF) collected data as directly “normal” or “abnormal”.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal CRP Values</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Central lab was not used in this study; the definitions of abnormal CRP followed participating hospitals’ standardized criteria. Case report form (CRF) collected data as directly “normal” or “abnormal”.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Sedimentation Rate (ESR) Values</title>
        <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. A higher rate is consistent with inflammation.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR) Values</title>
          <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. A higher rate is consistent with inflammation.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4" spread="31.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal ESR Values</title>
        <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. A higher rate is consistent with inflammation. Central lab was not used in this study; the definitions of abnormal ESR followed participating hospitals’ standardized criteria. CRF collected data as directly “normal” or “abnormal”.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal ESR Values</title>
          <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. A higher rate is consistent with inflammation. Central lab was not used in this study; the definitions of abnormal ESR followed participating hospitals’ standardized criteria. CRF collected data as directly “normal” or “abnormal”.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="394"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Values</title>
        <description>Hemoglobin levels were measured in gram per liter (g/L). Anemia was defined as an adult male with hemoglobin value &lt;120 g/L or an adult female with hemoglobin value &lt;110 g/L.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin Values</title>
          <description>Hemoglobin levels were measured in gram per liter (g/L). Anemia was defined as an adult male with hemoglobin value &lt;120 g/L or an adult female with hemoglobin value &lt;110 g/L.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.1" spread="18.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anemia</title>
        <description>Anemia was defined as an adult male with hemoglobin value &lt;120 g/L or an adult female with hemoglobin value &lt;110 g/L.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anemia</title>
          <description>Anemia was defined as an adult male with hemoglobin value &lt;120 g/L or an adult female with hemoglobin value &lt;110 g/L.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Anti-cyclic Citrullinated Peptide (ACCP) Antibody</title>
        <description>ACCP antibodies are important markers of bone erosion in RA. Central lab was not used in this study; the definitions of positive ACCP followed participating hospitals’ standardized criteria. CRF collected data as “positive” or “negative” directly.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Anti-cyclic Citrullinated Peptide (ACCP) Antibody</title>
          <description>ACCP antibodies are important markers of bone erosion in RA. Central lab was not used in this study; the definitions of positive ACCP followed participating hospitals’ standardized criteria. CRF collected data as “positive” or “negative” directly.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Positive Rheumatoid Factor (RF)</title>
        <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. Central lab was not used in this study; the definitions of positive RF followed participating hospitals’ standardized criteria. CRF collected data as “positive” or “negative” directly.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Positive Rheumatoid Factor (RF)</title>
          <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. Central lab was not used in this study; the definitions of positive RF followed participating hospitals’ standardized criteria. CRF collected data as “positive” or “negative” directly.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglyceride Values</title>
        <description>Normal range for triglyceride is &lt;1.7 millimoles per liter (mmol/L).</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Triglyceride Values</title>
          <description>Normal range for triglyceride is &lt;1.7 millimoles per liter (mmol/L).</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Triglyceride Values</title>
        <description>Normal range for triglyceride is &lt;1.7 mmol/L.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Triglyceride Values</title>
          <description>Normal range for triglyceride is &lt;1.7 mmol/L.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol Values</title>
        <description>Normal range for total cholesterol is &lt;5.2 mmol/L.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol Values</title>
          <description>Normal range for total cholesterol is &lt;5.2 mmol/L.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Total Cholesterol Values</title>
        <description>Normal range for total cholesterol is &lt;5.2 mmol/L.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Total Cholesterol Values</title>
          <description>Normal range for total cholesterol is &lt;5.2 mmol/L.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="233"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swollen Joint Count (SJC)</title>
        <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Swollen Joint Count (SJC)</title>
          <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28.</description>
          <population>Overall Population</population>
          <units>swollen joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="6.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tender Joint Count (TJC)</title>
        <description>Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joint Count (TJC)</title>
          <description>Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28.</description>
          <population>Overall Population</population>
          <units>tender joint count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Based on 28-Joint Count (DAS28)</title>
        <description>DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and Patient’s Global Assessment (PtGA) of disease activity (measured on a 0 to 100 mm Visual Analogue Scale [VAS] where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*square root (sqrt) (TJC28) + 0.28*sqrt(SJC28) + 0.70*natural logarithm (ln) (ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA of disease activity. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Based on 28-Joint Count (DAS28)</title>
          <description>DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and Patient’s Global Assessment (PtGA) of disease activity (measured on a 0 to 100 mm Visual Analogue Scale [VAS] where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*square root (sqrt) (TJC28) + 0.28*sqrt(SJC28) + 0.70*natural logarithm (ln) (ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA of disease activity. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing High Disease Activity to Clinical Remission Using the DAS28</title>
        <description>DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and PtGA of disease activity (measured on a 0 to 100 mm VAS where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA of disease activity. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing High Disease Activity to Clinical Remission Using the DAS28</title>
          <description>DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and PtGA of disease activity (measured on a 0 to 100 mm VAS where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA of disease activity. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="412"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Disease Activity Index (CDAI) Scores</title>
        <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and Physician’s Global Assessment (PGA) assessed on 0-10 centimeter (cm) VAS; 0 = no disease activity and 10 = worst disease activity. CDAI total score = 0-76. CDAI &lt;= 2.8 indicates clinical remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high (or severe) disease activity.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Disease Activity Index (CDAI) Scores</title>
          <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and Physician’s Global Assessment (PGA) assessed on 0-10 centimeter (cm) VAS; 0 = no disease activity and 10 = worst disease activity. CDAI total score = 0-76. CDAI &lt;= 2.8 indicates clinical remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high (or severe) disease activity.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="801"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" spread="15.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing High Disease Activity to Clinical Remission Using the CDAI</title>
        <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity. CDAI total score = 0-76. CDAI &lt;= 2.8 indicates clinical remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high (or severe) disease activity.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing High Disease Activity to Clinical Remission Using the CDAI</title>
          <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity. CDAI total score = 0-76. CDAI &lt;= 2.8 indicates clinical remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high (or severe) disease activity.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="801"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Simplified Disease Activity Index (SDAI)</title>
        <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity, and CRP (mg/dL). SDAI total score = 0-86. SDAI &lt;=3.3 indicates clinical remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high (or severe) disease activity.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Simplified Disease Activity Index (SDAI)</title>
          <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity, and CRP (mg/dL). SDAI total score = 0-86. SDAI &lt;=3.3 indicates clinical remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high (or severe) disease activity.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2" spread="18.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing High Disease Activity to Clinical Remission Using the SDAI</title>
        <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity, and CRP (mg/dL). SDAI total score = 0-86. SDAI &lt;=3.3 indicates clinical remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high (or severe) disease activity.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing High Disease Activity to Clinical Remission Using the SDAI</title>
          <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on 0-10 cm VAS; 0 = no disease activity and 10 = worst disease activity, and CRP (mg/dL). SDAI total score = 0-86. SDAI &lt;=3.3 indicates clinical remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high (or severe) disease activity.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>High disease activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate disease activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low disease activity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Duration of Treatment of Biological Agent</title>
        <description>Number of participants with duration of treatment of biological agent &lt;3 months, &gt;= 3 to &lt;6 months, &gt;= 6 to &lt;12 months, and &gt;= 12 months.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Duration of Treatment of Biological Agent</title>
          <description>Number of participants with duration of treatment of biological agent &lt;3 months, &gt;= 3 to &lt;6 months, &gt;= 6 to &lt;12 months, and &gt;= 12 months.</description>
          <population>Overall Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=3 to &lt;6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=6 to &lt;12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DAS28 by Duration of Treatment of Biological Agent</title>
        <description>DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and PtGA of disease activity (measured on a 0 to 100 mm VAS where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA of disease activity. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure in respective arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Duration of Biological Treatment &lt;3 Months</title>
            <description>Participants were divided into groups with different duration of treatment according to the months of using biological agent. This group included participants with duration of biological treatment &lt;3 months.</description>
          </group>
          <group group_id="O2">
            <title>Duration of Biological Treatment &gt;=3 to &lt;6 Months</title>
            <description>Participants were divided into groups with different duration of treatment according to the months of using biological agent. This group included participants with duration of biological treatment &gt;=3 to &lt;6 months.</description>
          </group>
          <group group_id="O3">
            <title>Duration of Biological Treatment &gt;=6 to &lt;12 Months</title>
            <description>Participants were divided into groups with different duration of treatment according to the months of using biological agent. This group included participants with duration of biological treatment &gt;=6 to &lt;12 months.</description>
          </group>
          <group group_id="O4">
            <title>Duration of Biological Treatment &gt;=12 Months</title>
            <description>Participants were divided into groups with different duration of treatment according to the months of using biological agent. This group included participants with duration of biological treatment &gt;=12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28 by Duration of Treatment of Biological Agent</title>
          <description>DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and PtGA of disease activity (measured on a 0 to 100 mm VAS where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA of disease activity. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure in respective arms.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="1.45"/>
                    <measurement group_id="O2" value="3.5" spread="1.44"/>
                    <measurement group_id="O3" value="3.9" spread="1.42"/>
                    <measurement group_id="O4" value="3.2" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>F test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DAS28 by Biological Agent as Monotherapy or Combination With csDMARDs</title>
        <description>Biological agent monotherapy meant participants using a biological agent without concomitant csDMARDs. DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and PtGA of disease activity (measured on a 0 to 100 mm VAS where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Biological Agent as Monotherapy</title>
            <description>Participants were divided into two groups according to whether using biological agent (namely, biological agent concomitant with csDMARDs treatment group and biological agent without csDMARDs treatment group). This group included participants using biological agent without concomitant csDMARDs.</description>
          </group>
          <group group_id="O2">
            <title>Biological Agent as Combination With csDMARDs</title>
            <description>Participants were divided into two groups according to whether using biological agent (namely, biological agent concomitant with csDMARDs treatment group and biological agent without csDMARDs treatment group). This group included participants using biological agent with concomitant csDMARDs.</description>
          </group>
        </group_list>
        <measure>
          <title>DAS28 by Biological Agent as Monotherapy or Combination With csDMARDs</title>
          <description>Biological agent monotherapy meant participants using a biological agent without concomitant csDMARDs. DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour) or CRP (mg/dL), and PtGA of disease activity (measured on a 0 to 100 mm VAS where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using following formulas: DAS28-ESR = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014*PtGA of disease activity; DAS28-CRP = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(10*CRP+1) + 0.014*PtGA. DAS28-ESR was adopted to calculate DAS28 if effective ESR data was available; otherwise DAS28-CRP was adopted to calculate DAS28. Total score range: 0-10, higher score=more disease activity. DAS28 &lt;=3.2 implied low disease activity, DAS &gt;3.2 to 5.1 implied moderate disease activity and DAS &gt;5.1 implied high disease activity, and DAS28 &lt;2.6 = clinical remission.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="356"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.76"/>
                    <measurement group_id="O2" value="4.3" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0108</p_value>
            <method>F test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician’s Global Assessment (PGA) of Disease Activity</title>
        <description>PGA of disease activity was measured on a 0 to 10 centimeter (cm) VAS, with 0 cm = no disease activity and 10 cm = extreme disease activity.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Physician’s Global Assessment (PGA) of Disease Activity</title>
          <description>PGA of disease activity was measured on a 0 to 10 centimeter (cm) VAS, with 0 cm = no disease activity and 10 cm = extreme disease activity.</description>
          <population>Overall Population</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient’s Global Assessment (PtGA) of Disease Activity</title>
        <description>PtGA of disease activity was measured on a 0 to 10 cm VAS, with 0 cm = very well controlled and 10 cm = very poorly controlled.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Patient’s Global Assessment (PtGA) of Disease Activity</title>
          <description>PtGA of disease activity was measured on a 0 to 10 cm VAS, with 0 cm = very well controlled and 10 cm = very poorly controlled.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="801"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</title>
        <description>The HAQ consists of 20 questions in 8 categories (dressing and grooming, rising, eating, walking, reach, grip, hygiene, and carrying out daily activities). Each question has 4 response options, ranging from “no difficulty” to “unable to do”, corresponding to scores from 0 to 3. HAQ total score = sum of each of the 20 items' scores, with a summary score ranging from 0 to 60, where higher score indicates greater disability.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire-Disability Index (HAQ-DI) Score</title>
          <description>The HAQ consists of 20 questions in 8 categories (dressing and grooming, rising, eating, walking, reach, grip, hygiene, and carrying out daily activities). Each question has 4 response options, ranging from “no difficulty” to “unable to do”, corresponding to scores from 0 to 3. HAQ total score = sum of each of the 20 items' scores, with a summary score ranging from 0 to 60, where higher score indicates greater disability.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="800"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" spread="13.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant’s Fatigue Assessment</title>
        <description>Participants scored the fatigue on 10 cm VAS from 0 = no fatigue to 10 = very fatigue.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Participant’s Fatigue Assessment</title>
          <description>Participants scored the fatigue on 10 cm VAS from 0 = no fatigue to 10 = very fatigue.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="801"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant's Pain Assessment</title>
        <description>Participants scored the intensity of pain produced by RA on 10 cm VAS from 0 = no pain to 10 = extreme pain.</description>
        <time_frame>Day 1 (enrollment visit)</time_frame>
        <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Population</title>
            <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
          </group>
        </group_list>
        <measure>
          <title>Participant's Pain Assessment</title>
          <description>Participants scored the intensity of pain produced by RA on 10 cm VAS from 0 = no pain to 10 = extreme pain.</description>
          <population>Overall Population. Number of participants analyzed = participants evaluable for this outcome measure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="801"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 (enrollment visit)</time_frame>
      <desc>Overall population</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall Population</title>
          <description>Participants diagnosed with RA according to ACR 1987 criteria who were using biological DMARDs approved in China for RA treatment were observed at the single study visit (enrollment visit).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="802"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal liver function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Amyosthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="802"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythra</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="802"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="802"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-LaRoche</organization>
      <phone>800-821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

